GlobeNewsWire
30 May 2026, 12:00 UTC · 16w ago
Verdict
Headline takes no side. We score REPL +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The IGNYTE trial showed that 83.5% of patients responding to RP1 plus nivolumab were alive at the 3-year landmark for anti-PD-1 failed melanoma.
More positive than 98% of claims this week
Nearly half of all treated patients in the IGNYTE study were alive at the three-year mark.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 91% of claims this week
Replimune is currently awaiting FDA review of its Biologics License Application (BLA) for RP1.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company presented positive 3-year overall survival data from the IGNYTE clinical trial for its lead product candidate RP1.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
4d ago
+50.4%
Price agrees with the score
$13.07 vs $8.69 close before publication (May 29) · not market-adjusted
REPL chart →
